share_log

UPLOAD: Others

UPLOAD: Others

UPLOAD:其他
美股sec公告 ·  05/14 13:05
Moomoo AI 已提取核心信息
NeuroSense Therapeutics Ltd., a company specializing in neurological treatments, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on May 10, 2024, will not undergo review. The SEC's communication, dated May 14, 2024, was addressed to Alon Ben-Noon, CEO of NeuroSense Therapeutics, and was sent from the Division of Corporation Finance, Office of Life Sciences. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Tim Buchmiller.
NeuroSense Therapeutics Ltd., a company specializing in neurological treatments, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on May 10, 2024, will not undergo review. The SEC's communication, dated May 14, 2024, was addressed to Alon Ben-Noon, CEO of NeuroSense Therapeutics, and was sent from the Division of Corporation Finance, Office of Life Sciences. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Tim Buchmiller.
美国证券交易委员会(SEC)已通知专注于神经治疗的公司NeuroSense Therapeutics Ltd.,其提交于2024年5月10日的F-1表格注册声明将不经过审核。SEC的通信日期为2024年5月14日,信件是寄给NeuroSense Therapeutics的CEO Alon Ben-Noon的,发件人是公司金融部生命科学办公室。SEC的信件还涉及460和461条规则,这些规则与请求加速注册过程有关。此外,SEC提醒公司及其管理层,无论SEC的审核水平如何或缺乏审核,他们都有责任确保其披露信息的准确性和充分性。如需进一步查询,SEC提供了Tim Buchmiller的联系信息。
美国证券交易委员会(SEC)已通知专注于神经治疗的公司NeuroSense Therapeutics Ltd.,其提交于2024年5月10日的F-1表格注册声明将不经过审核。SEC的通信日期为2024年5月14日,信件是寄给NeuroSense Therapeutics的CEO Alon Ben-Noon的,发件人是公司金融部生命科学办公室。SEC的信件还涉及460和461条规则,这些规则与请求加速注册过程有关。此外,SEC提醒公司及其管理层,无论SEC的审核水平如何或缺乏审核,他们都有责任确保其披露信息的准确性和充分性。如需进一步查询,SEC提供了Tim Buchmiller的联系信息。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息